Arabic Arabic English English French French German German
dark

RubrYc Therapeutics Announces Series A2 Preferred Equity Financing, Collaboration, and RTX-003 License with iBio, Inc.

RubrYc Therapeutics, Inc. (“RubrYc”) and iBio, Inc. (“iBio”, NYSEA: IBIO) announced today the closing of RubrYc’s Series A2 Preferred Financing, and concomitant License and Collaboration Agreements directed towards the research, development, and commercialization of epitope-targeted antibody therapeutics. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

MassBio Industry Snapshot Predicts 40,000 New Biopharma Jobs Over the Next 10 Years

Next Post

Rapid Dose Therapeutics Reports Fiscal Year 2021 Financial Results

Related Posts
Total
0
Share